RECI.L
Real Estate Credit Investments Limited
LSEGBpEQUITY
DELAYED
Last price
117.00
▼ 0.50 (0.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
118.50
Prev close
117.50
Day high
118.50
Day low
117.00
Volume
265.00K
Market cap
—
P/E (TTM)
—
52W range
112.00 – 130.41
Day trading desk
Gap from prior close
+0.85%
Prior close 117.50
VWAP
117.53
-0.45% from price
Relative volume
—
—
Session range
1.28%
117.00 – 118.50
Position in range
0%
Near session low
ATR (14D)
2.31
1.97% of price
Prior day high
118.50
PDH
Prior day low
116.50
PDL
Bid / ask spread
—
Quote not published
Session volume
387.04K
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.27%
+0.1%
1M
+0.86%
-2.9%
3M
+0.86%
-2.2%
6M
-8.59%
-19.7%
YTD
-5.26%
-17.6%
1Y
-5.65%
-25.6%
3Y
-7.51%
-81.7%
5Y
-24.76%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on RECI.L open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $21.49M | $30.10M | $27.15M | $26.37M | -28.6% |
| Operating revenue | $21.49M | $30.10M | $27.15M | $26.37M | -28.6% |
| Selling, general & admin | $46.00K | $2.50M | $1.78M | $1.85M | -98.2% |
| Total operating expense | $6.30M | $7.29M | $5.30M | $5.82M | -13.5% |
| Pre-tax income | $15.19M | $22.82M | $21.86M | $20.55M | -33.4% |
| Net income | $15.19M | $22.82M | $21.86M | $20.55M | -33.4% |
| Net income to common | $15.19M | $22.82M | $21.86M | $20.55M | -33.4% |
| Basic EPS | 0.07 | 0.10 | 0.10 | 0.09 | -32.4% |
| Diluted EPS | 0.07 | 0.10 | 0.10 | 0.09 | -32.8% |
| Basic shares | 221.66M | 222.88M | 228.78M | 229.33M | -0.5% |
| Diluted shares | 221.66M | 222.88M | 228.78M | 229.33M | -0.5% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $18.51M | $19.30M | $18.29M | $14.08M | -4.1% |
| Total assets | $425.36M | $391.71M | $352.25M | $418.99M | +8.6% |
| Total debt | $118.44M | $70.85M | $23.79M | $80.44M | +67.2% |
| Total liabilities | $119.48M | $73.36M | $25.87M | $82.02M | +62.9% |
| Shareholder equity | $305.89M | $318.36M | $326.38M | $336.97M | -3.9% |
| Net tangible assets | $305.89M | $318.36M | $326.38M | $336.97M | -3.9% |
| Shares issued | 229.33M | 229.33M | 229.33M | 229.33M | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $15.19M | $22.82M | $21.86M | $20.55M | -33.4% |
| Change in working capital | -$921.00K | $1.96M | -$1.77M | $3.02M | -147.1% |
| Operating cash flow | -$13.27M | -$10.69M | $96.49M | $18.31M | -24.1% |
| Share buybacks | -$1.07M | -$4.17M | -$5.02M | $0 | +74.4% |
| Dividends paid | -$26.59M | -$26.67M | -$27.42M | -$27.52M | +0.3% |
| Financing cash flow | $12.48M | $11.69M | -$92.28M | -$51.61M | +6.8% |
| Free cash flow | -$13.27M | -$10.69M | $96.49M | $18.31M | -24.1% |
| End cash position | $18.51M | $19.30M | $18.29M | $14.08M | -4.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $18.51M | $38.16M | $19.30M | -51.5% |
| Total assets | $425.36M | $431.53M | $391.71M | -1.4% |
| Total debt | $118.44M | $107.21M | $70.85M | +10.5% |
| Total liabilities | $119.48M | $117.51M | $73.36M | +1.7% |
| Shareholder equity | $305.89M | $314.02M | $318.36M | -2.6% |
| Net tangible assets | $305.89M | $314.02M | $318.36M | -2.6% |
| Shares issued | 229.33M | 229.33M | 229.33M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
117.60
-0.51% from price
SMA 20
117.23
-0.19% from price
SMA 50
116.46
+0.46% from price
SMA 100
117.01
-0.01% from price
SMA 200
120.16
-2.63% from price
EMA 12
117.40
-0.34% from price
EMA 26
117.04
-0.03% from price
EMA 50
116.91
+0.08% from price
RSI (14)
49.9
Neutral
MACD (12,26,9)
0.36
Hist -0.01
ATR (14)
2.31
1.97% of price
Realised vol 30D
11.7%
Annualised
Bollinger upper
118.72
20, 2σ
Bollinger lower
115.73
20, 2σ
50 / 200 cross
Death
116.46 vs 120.16
Trend bias
Below 200
-2.63%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.16
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
11.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-12.3%
Peak to trough
Max drawdown 5Y
-28.3%
Peak to trough
ATR 14
2.31
1.97% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
PR Newswire · 8m ago
India police used excessive force during protests: Amnesty
AFP · 11m ago
AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue?
Insider Monkey · 13m ago
California expected to seek TV channel sales from Paramount-Warner, WSJ reports
Reuters · 16m ago
Here's the Smartest S&P 500 Dividend Stock to Buy With $1,000 Right Now -- and It's Sporting a 6.8% Dividend Yield
Motley Fool · 18m ago
Walmart's top-rated mini dresser is just $26 during a Flash deal
TheStreet · 23m ago
Novo Nordisk Expands Its AI Push With AWS, But Can It Accelerate Drug Discovery?
Insider Monkey · 24m ago
The “No-Contest Clause”: One Sentence That Makes Challenging Your Will Cost a Child Everything You Left Them.
24/7 Wall St. · 24m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.